E

5 early developments to watch out for at AACR21

What's hot in early preclinical development to watch out for?

April 5, 2021
E

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020
E

Are gamma delta T cells ready yet for prime time?

Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?

July 1, 2020
E

The Potential of CAR-NK Cells for Cancer Immunotherapy

Will CAR-NK cells follow CAR-T cell therapies and hit prime time?

May 13, 2020
E

JPM20 Highlights from Day 2

Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco

January 14, 2020
E

Are 𝞬𝝳 T cells immuno-suppressive and should we delete them?

As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative

April 17, 2019
E

Gamma delta T cell cancer immunotherapy in China

What can we learn about gamma delta T cell cancer immunotherapy in China?

February 28, 2019
E
Aerial View Thames Estuary

Emerging Gamma Delta T Cell Cancer Immunotherapy Landscape

A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development

February 27, 2019
E

Are gamma delta T cells the next wave of cell therapies?

Can we make novel allogeneic cell therapies with γδ T cells? We find out!

February 26, 2019
E

A Voyage of Discovery

Can γδ T cells be employed as a therapeutic against cancer?

February 25, 2019
E
TC BioPharm Office Building

TC BioPharm leads the way in allogeneic gamma delta T cells

TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020

March 4, 2019